Capha Pharmaceuticals Inc.
FPSUF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.01 | -0.01 | 0.01 |
| FCF Yield | -766.16% | -859.32% | -704.77% | -581.68% |
| EV / EBITDA | -11.21 | -9.34 | -7.35 | -7.73 |
| Quality | ||||
| ROIC | 485.83% | 497.92% | -57.67% | -75.23% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.00 | 1.35 | 1.05 | 1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 3.19% | -19.29% | -29.80% | 37.80% |
| Safety | ||||
| Net Debt / EBITDA | -11.02 | -9.18 | -7.20 | -7.54 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |